Novo Soars on Wegovy Pill Approval; Huntington Ingalls Rallies; Orsted Declines

On this episode of Stock Movers:
- Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term.
- Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays.
- Shares of Copenhagen-listed Orsted (ORSTED DC) declined after the company said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday. Orsted said its farms — Revolution Wind and Sunrise Wind — had secured all the required federal and state permits, including consulting “closely and directly” with US authorities to “to evaluate and address potential impacts to national security and defense capabilities.

See omnystudio.com/listener for privacy information.